Cite
HARVARD Citation
Boyle, E. et al. (2019). Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial. British journal of haematology. pp. 319-327. [Online].